Access to the anti-tumour necrosis factor alpha (TNF-α inhibitor) adalimumab, has been widened with the funding of the biosimilar Amgevita. Dosage restrictions have been removed, and the Special Authority renewal period has been extended to two years. From 1 March 2022, all new patients starting adalimumab receive Amgevita.
From 1 October 2022, Amgevita becomes the primary funded option for adalimumab. Patients who are already stable on the reference product, Humira, can be transitioned to Amgevita in primary care during the period where both brands are funded (1 March to 1 October 2022).
Exemptions are in place for continued funded use of Humira for certain patients who need to remain on, or move back to, the reference medicine. However, there is no provision for patients who have never used Humira to transition from Amgevita to funded Humira.